Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.15 (market cap $3.80B). The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is far larger — about 279× Citius Pharmaceuticals Inc's market cap, and Vanguard Global ex-US Real Estate Index Fd ETF is more actively traded (277,049 versus 132,438). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days on average.
| CTXR | VNQI | |
|---|---|---|
Market Cap | $13.62M | $3.80B |
Volume | 132,438 | 277,049 |
Sector | Health | — |
52-Week High | $1.82 | $50.76 |
52-Week Low | $0.48 | $41.81 |
Typical Hold Time | 17 Days | 95 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
VNQI trades at $41.82, showing minimal daily movement with a 0.02% gain. Technical indicators signal bearish momentum as moving averages show unanimous selling pressure, though oscillators remain neutral. Recent news highlights a significant 45.9% drop in short interest in September 2026, while the fund continues to offer competitive advantages including exposure to international real estate markets across 30+ countries and a higher dividend yield compared to domestic alternatives.
The ETF faces headwinds from global real estate market volatility but maintains structural strengths through diversification and cost efficiency. Key risks include international economic sensitivity and currency fluctuations, while the reduced short interest suggests some investor confidence. Long-term appeal lies in international real estate exposure and income generation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
